CoChat

Mechanisms of Resistance to KRASG12C Inhibitors

Open access
Dunnett-Kane, Victoria, Nicola, Pantelis, Blackhall, Fiona, Lindsay, Colin · 2021 · Cancers
Cited by 117

The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.

Abstract

KRAS is one of the most common human oncogenes, but concerted efforts to produce direct inhibitors have largely failed, earning KRAS the title of “undruggable”. Recent efforts to produce subtype specific inhibitors have been more successful, and several KRASG12C inhibitors have reached clinical trials, including adagrasib and sotorasib, which have shown early evidence of efficacy in patients. Lessons from other inhibitors of the RAS pathway suggest that the effect of these drugs will be limited in vivo by the development of drug resistance, and pre-clinical studies of G12C inhibitors have identified evidence of this. In this review we discuss the current evidence for G12C inhibitors, the mechanisms of resistance to G12C inhibitors and potential approaches to overcome them. We discuss possible targets of combination therapy, including SHP2, receptor tyrosine kinases, downstream effectors and PD1/PDL1, and review the ongoing clinical trials investigating these inhibitors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/cancers13010151

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 55 references

Research works printed but not linked: 21

  1. Pakkala, 2018, Personalized therapy for lung cancer: Striking a moving target, JCI Insight, 3, 120858, 10.1172/jci.insight.120858 · DOI · Paper page
  2. Wang, 2012, Ras inhibition via direct Ras binding—Is there a path forward?, Bioorganic Med. Chem. Lett., 22, 5766, 10.1016/j.bmcl.2012.07.082 · DOI · Paper page
  3. Lindsay, 2018, KRAS: Reasons for optimism in lung cancer, Eur. J. Cancer, 99, 20, 10.1016/j.ejca.2018.05.001 · DOI · Paper page
  4. Ahearn, 2011, Regulating the regulator: Post-translational modification of RAS, Nat. Rev. Mol. Cell Biol., 13, 39, 10.1038/nrm3255 · DOI · Paper page
  5. Brunner, 2003, Farnesyltransferase inhibitors: An overview of the results of preclinical and clinical investigations, Cancer Res., 63, 14522880
  6. Kohl, 1995, Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice, Nat. Med., 1, 792, 10.1038/nm0895-792 · DOI · Paper page
  7. Heymach, 2004, Phase II study of the farnesyl transferase inhibitor R115777 in patients with sensitive relapse small-cell lung cancer, Ann. Oncol., 15, 1187, 10.1093/annonc/mdh315 · DOI
  8. Ho, 2018, Preliminary results from a phase II trial of tipifarnib in squamous cell carcinomas (SCCs) with HRAS mutations, Ann. Oncol., 29, viii373, 10.1093/annonc/mdy287.002 · DOI
  9. Burrows, 2020, Antitumor activity of tipifarnib and PI3K pathway inhibitors in HRAS-associated head and neck squamous cell carcinoma, Eur. J. Cancer, 138, S43, 10.1016/S0959-8049(20)31191-6 · doi:10.1016/s0959-8049(20)31191-6
  10. Lindsay, 2019, Direct Ras G12C inhibitors: Crossing the rubicon, Br. J. Cancer, 121, 197, 10.1038/s41416-019-0499-1 · DOI · Paper page
  11. Hayashi, 2013, Postprogression Survival in Patients with Advanced Non–Small-Cell Lung Cancer Who Receive Second-Line or Third-Line Chemotherapy, Clin. Lung Cancer, 14, 261, 10.1016/j.cllc.2012.09.006 · DOI
  12. Franke, 2008, PI3K/Akt: Getting it right matters, Oncogene, 27, 6473, 10.1038/onc.2008.313 · DOI · Paper page
  13. Singh, 2009, A Gene Expression Signature Associated with “K-Ras Addiction” Reveals Regulators of EMT and Tumor Cell Survival, Cancer Cell, 15, 489, 10.1016/j.ccr.2009.03.022 · DOI · Paper page
  14. Little, 2011, Amplification of the Driving Oncogene, KRAS or BRAF, Underpins Acquired Resistance to MEK1/2 Inhibitors in Colorectal Cancer Cells, Sci. Signal., 4, ra17, 10.1126/scisignal.2001752 · DOI · Paper page
  15. Corcoran, 2012, EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF-Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib, Cancer Discov., 2, 227, 10.1158/2159-8290.CD-11-0341 · DOI · Paper page
  16. Bendell, 2020, Intermittent dosing of RMC-4630, a potent, selective inhibitor of SHP2, combined with the MEK inhibitor cobimetinib, in a phase 1b/2 clinical trial for advanced solid tumors with activating mutations of RAS signaling, Eur. J. Cancer, 138, S8, 10.1016/S0959-8049(20)31089-3 · DOI
  17. Fedele, C., Li, S., Teng, K.W., Foster, C.J., Peng, D.H., Ran, H., Mita, P., Geer, M.J., Hattori, T., and Koide, A. (2021). SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling. J. Exp. Med., 218. · DOI · Paper page
  18. Engelman, 2008, Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers, Nat. Med., 14, 1351, 10.1038/nm.1890 · DOI · Paper page
  19. Alagesan, 2015, Combined MEK and PI3K Inhibition in a Mouse Model of Pancreatic Cancer, Clin. Cancer Res., 21, 396, 10.1158/1078-0432.CCR-14-1591 · DOI · Paper page
  20. Juric, 2014, A phase 1b dose-escalation study of BYL719 plus binimetinib (MEK162) in patients with selected advanced solid tumors, J. Clin. Oncol., 32, 9051, 10.1200/jco.2014.32.15_suppl.9051 · DOI · Paper page
  21. Foster, 2014, Metabolic vulnerability of KRAS-driven cancer cells, Mol. Cell. Oncol., 1, e963445, 10.4161/23723548.2014.963445 · DOI

Cited by

See all 117

Metadata

Authors
Dunnett-Kane, V., Nicola, P., Blackhall, F., & Lindsay, C.
Venue
Cancers
Publisher
MDPI AG
Published
2021-01-05
Volume
13
Issue
1
Pages
151
ISSN
2072-6694 (ISSN-L)
OpenAlex
W3119145039
Cited by
117
References
55
FWCI
6.98
Type
journal article
Language
en
Open access
gold
Funders
Cancer Research UK (A25254, A20465)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Mechanisms of Resistance to KRASG12C Inhibitors. https://app.cochat.ai/papers/10.3390/cancers13010151
The paper
Dunnett-Kane, V., Nicola, P., Blackhall, F., & Lindsay, C. (2021). Mechanisms of Resistance to KRASG12C Inhibitors. Cancers. https://doi.org/10.3390/cancers13010151

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.